Investigation of dry powder aerosolization mechanisms in different channel designs.
Aerosolization efficiency is the key characteristic of dry powder inhaler (DPI). However, lack of knowledge about powder dispersion and deposition is still a major obstacle to further improve inhaler. In the current work, both the in vitro deposition experiments and numerical simulations were employed to investigate the performance of three different DPI channel designs. The powder model was commercially available Seretide Accuhaler, which contains carrier lactose and drug mixture of fluticasone propionate (FP) and salmeterol xinafoate (SX). The in vitro results, such as the mass mediate aerodynamic diameter (MMAD), fine particle fraction (FPF) and fine particle dose (FPD), were obtained by the Next Generation Impactor (NGI). The values of MMAD were significantly (p<0.05) affected by channel design. However, based on the FPF result, the three channel designs had similar capabilities of aerosolization. It was demonstrated that particle-wall collision was the dominant mechanism for the detachment and de-agglomeration at these conditions. Furthermore, good linear correlations were found between the FPD values on the first 4 stages of NGI and the outlet velocities of their corresponding particles, which would be used for a potential on-line approach to the evaluation of DPI efficiency.
School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China; Postharvest Technology Research Laboratory, South African Research Chair in Postharvest Technology, Stellenbosch University, Stellenbosch 7602, South Africa.
Lan
L
Chen
Rui-Lin
RL
Heng
Mulugeta Admasu
MA
Delele
Jian
J
Cai
Di-Zheng
DZ
Du
Umezuruike Linus
UL
Opara
D000336:Aerosols; D000420:Albuterol / Q000031:analogs & derivatives; D000730:Androstadienes; D004338:Drug Combinations; D058995:Dry Powder Inhalers / Q000295:instrumentation*; D004867:Equipment Design; D000068297:Fluticasone-Salmeterol Drug Combination
D000336:Aerosols; D000730:Androstadienes; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D000420:Albuterol
Aerosolization; Carrier-based dry powder; Computational fluid dynamics; Dry powder inhaler; Fine particle fraction; Next generation impactor